Organization
Universitätsklinikum Schleswig-Holstein
1 abstract
1 poster
Abstract
Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.Org: Onkologie Ravensburg, University Women’s Hospital, Paracelsus Medical University, Winicker Norimed GmbH, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,